Company intelligence / Profile preview

Amathus Therapeutics, Inc.

Cambridge, Massachusetts, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Amathus Therapeutics is developing small molecule modulators of organelle-specific chaperones for genetically defined diseases. The company has demonstrated activation of molecular chaperones is possible and has shown potential to address core mitochondrial dysfunction with specificity.

Therapeutic areas: NeurologyNephrology
Modalities: Small molecules
Industry: Biotech

Partnerships

Merck (strategic collaboration announced March 17, 2021)

Beyond the preview

Go deeper on Amathus Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amathus Therapeutics, Inc..

Explore the full profile